Abstract | BACKGROUND: We previously reported no difference in the efficacies of high-dose alternate-day (ADT) and daily-dose ( DDT) prednisolone therapies in myositis patients, but that the incidence of side effects was lower in the former. The aim of the present study was to compare the long-term outcomes of both treatments in polymyositis patients. METHODS: We compared clinical courses, efficacies, adverse reactions, and outcomes of 115 consecutive, biopsy-proven polymyositis patients treated between 1970 and 2008 with ADT (32 patients) or DDT (83 patients). RESULTS: Mean onset ages, disease severity, incidences of malignancy, and response rates did not differ between the ADT and DDT groups. Adverse reactions (incidence of diabetes) were significantly higher in the DDT group. In this group, the incidences of hyperlipidemia, infection, hypertension, and psychiatric symptoms were also slightly higher, but not significantly so. The 20-year survival rate of the ADT group (68%) was significantly higher (p = 0.0112) than that of the DDT group (37%). CONCLUSION: ADT might be useful as an initial treatment option for polymyositis.
|
Authors | Makoto Uchino, Satoshi Yamashita, Katsuhisa Uchino, Akio Hara, Tatsuya Koide, Tomohiro Suga, Tomoo Hirahara, En Kimura, Taro Yamashita, Akihiko Ueda, Ryoichi Kurisaki, Junko Suzuki, Shoji Honda, Yasushi Maeda, Teruyuki Hirano |
Journal | European neurology
(Eur Neurol)
Vol. 68
Issue 2
Pg. 117-21
( 2012)
ISSN: 1421-9913 [Electronic] Switzerland |
PMID | 22805652
(Publication Type: Comparative Study, Journal Article)
|
Copyright | Copyright © 2012 S. Karger AG, Basel. |
Chemical References |
- Anti-Inflammatory Agents
- Prednisolone
|
Topics |
- Adult
- Aged
- Anti-Inflammatory Agents
(therapeutic use)
- Diabetes Mellitus
(chemically induced)
- Drug Administration Schedule
- Female
- Humans
- Longitudinal Studies
- Male
- Middle Aged
- Polymyositis
(drug therapy)
- Prednisolone
(therapeutic use)
- Survival Rate
- Treatment Outcome
|